Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Irradiation Decreases the Neuroendocrine Biomarker Pro-Opiomelanocortin in Small Cell Lung Cancer Cells In Vitro and In Vivo.

Meredith SL, Bryant JL, Babur M, Riddell PW, Behrouzi R, Williams KJ, White A.

PLoS One. 2016 Feb 5;11(2):e0148404. doi: 10.1371/journal.pone.0148404. eCollection 2016.

2.

Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients.

Stovold R, Meredith SL, Bryant JL, Babur M, Williams KJ, Dean EJ, Dive C, Blackhall FH, White A.

Br J Cancer. 2013 Apr 30;108(8):1704-11. doi: 10.1038/bjc.2013.112. Epub 2013 Mar 21.

3.

Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells.

Stovold R, Blackhall F, Meredith S, Hou J, Dive C, White A.

Lung Cancer. 2012 Jun;76(3):263-8. doi: 10.1016/j.lungcan.2011.11.015. Epub 2011 Dec 15. Review.

PMID:
22177533
4.

The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells.

Kalari S, Jung M, Kernstine KH, Takahashi T, Pfeifer GP.

Oncogene. 2013 Jul 25;32(30):3559-68. doi: 10.1038/onc.2012.362. Epub 2012 Aug 20.

5.

Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype.

Hamilton G, Hochmair M, Rath B, Klameth L, Zeillinger R.

Cell Adh Migr. 2016 Jul 3;10(4):360-7. doi: 10.1080/19336918.2016.1155019. Epub 2016 Feb 26.

6.

Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer.

Salcido CD, Larochelle A, Taylor BJ, Dunbar CE, Varticovski L.

Br J Cancer. 2010 May 25;102(11):1636-44. doi: 10.1038/sj.bjc.6605668. Epub 2010 Apr 27.

7.

N-acetylglucosaminyltransferase V modulates radiosensitivity and migration of small cell lung cancer through epithelial-mesenchymal transition.

Huang C, Huang M, Chen W, Zhu W, Meng H, Guo L, Wei T, Zhang J.

FEBS J. 2015 Nov;282(22):4295-306. doi: 10.1111/febs.13419. Epub 2015 Sep 21.

8.

Glucocorticoid inhibition of ACTH peptides: small cell lung cancer cell lines are more resistant than pituitary corticotroph adenoma cells.

Farrell WE, Stewart MF, Clark AJ, Crosby SR, Davis JR, White A.

J Mol Endocrinol. 1993 Feb;10(1):25-32.

PMID:
8383976
9.

Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes.

Krohn A, Ahrens T, Yalcin A, Plönes T, Wehrle J, Taromi S, Wollner S, Follo M, Brabletz T, Mani SA, Claus R, Hackanson B, Burger M.

PLoS One. 2014 Jun 24;9(6):e100249. doi: 10.1371/journal.pone.0100249. eCollection 2014.

10.

Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.

Ito T, Kudoh S, Ichimura T, Fujino K, Hassan WA, Udaka N.

Hum Cell. 2017 Jan;30(1):1-10. doi: 10.1007/s13577-016-0149-3. Epub 2016 Oct 26. Review.

PMID:
27785690
11.

Expression of the pro-opiomelanocortin gene in lung neuroendocrine tumours: in situ hybridization and immunohistochemical studies.

Black M, Carey FA, Farquharson MA, Murray GD, McNicol AM.

J Pathol. 1993 Mar;169(3):329-34.

PMID:
8388056
12.

Notch1 signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma.

Wael H, Yoshida R, Kudoh S, Hasegawa K, Niimori-Kita K, Ito T.

Lung Cancer. 2014 Aug;85(2):131-40. doi: 10.1016/j.lungcan.2014.05.001. Epub 2014 May 13.

PMID:
24888228
13.
14.

Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells.

Pettersson HM, Pietras A, Munksgaard Persson M, Karlsson J, Johansson L, Shoshan MC, Påhlman S.

Mol Cancer Ther. 2009 Jan;8(1):160-70. doi: 10.1158/1535-7163.MCT-08-0595.

15.

Class III/IV POU transcription factors expressed in small cell lung cancer cells are involved in proneural/neuroendocrine differentiation.

Ishii J, Sato H, Yazawa T, Shishido-Hara Y, Hiramatsu C, Nakatani Y, Kamma H.

Pathol Int. 2014 Sep;64(9):415-22. doi: 10.1111/pin.12198.

PMID:
25243889
16.

Functional analysis of the human pro-opiomelanocortin promoter in the small cell lung carcinoma cell line DMS-79.

Picon A, Leblond-Francillard M, Raffin-Sanson ML, Lenne F, Bertagna X, de Keyzer Y.

J Mol Endocrinol. 1995 Oct;15(2):187-94.

PMID:
8800643
17.

YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.

Horie M, Saito A, Ohshima M, Suzuki HI, Nagase T.

Cancer Sci. 2016 Dec;107(12):1755-1766. doi: 10.1111/cas.13078. Epub 2016 Nov 25.

18.

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.

Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA.

Oncotarget. 2017 Apr 25;8(17):28575-28587. doi: 10.18632/oncotarget.15338.

19.

Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.

Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, Karnezis AN, Sweet-Cordero EA, Sage J.

Cancer Res. 2010 May 15;70(10):3877-83. doi: 10.1158/0008-5472.CAN-09-4228. Epub 2010 Apr 20.

20.

Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells.

Zhang Z, Zhou Y, Qian H, Shao G, Lu X, Chen Q, Sun X, Chen D, Yin R, Zhu H, Shao Q, Xu W.

Cell Death Dis. 2013 May 16;4:e633. doi: 10.1038/cddis.2013.152.

Supplemental Content

Support Center